Tyra Biosciences (TYRA) Stock Forecast & Price Target

Tyra Biosciences is supported by a differentiated FGFR3-selective platform that could address large unmet needs in targeted oncology and achondroplasia, while its oral, continuous target coverage offers a practical advantage over earlier FGFR inhibitors. The clean 60 mg safety profile, with 0/22 Grade 3 treatment-related adverse events and no clinically significant hyperphosphatemia, nail, or ocular toxicity, strengthens the case for chronic dosing in adjuvant IR-NMIBC and pediatric disease, where tolerability is critical. Although SURF302 missed the ablative efficacy bar, the company still has multiple near-term catalysts, including BEACH301 sentinel data in 1Q27, SURF303 data in 2027, and a 2027 adjuvant Phase 3 start, while the current valuation appears to underappreciate the breadth of the 3x3 strategy.

Tyra Biosciences is viewed cautiously because its lead programs have not yet shown the kind of differentiated, reproducible efficacy needed to de-risk commercialization, with SURF302’s 57% 3-month CR and 64% best overall CR below the stated ≥70% bar and far behind competing benchmarks of 89% and 90%. The bearish view is reinforced by the need for BEACH301 to clear >6cm/year absolute height velocity without chronic pediatric safety concerns, yet the company has only cleared five sentinel dose levels and still awaits initial 6-month data from ~25 children at end-1Q27. Valuation remains highly contingent on uncertain clinical outcomes, as the model assigns only 20% probability of approval in urothelial carcinoma, 40% in achondroplasia and hypochondroplasia, and 35% for TYRA-200, while also flagging dilution and longer registrational risk.